- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Imfinzi granted FDA Priority Review for SCLC
AnnouncementREG - AstraZeneca PLC - Calquence approved in CLL in the US
AnnouncementREG - AstraZeneca PLC - Qtrilmet approved in the EU for treatment of T2D
AnnouncementREG - AstraZeneca PLC - FDA accepts regulatory submission for selumetinib
AnnouncementREG - AstraZeneca PLC - Anifrolumab demonstrated superiority in TULIP 2
AnnouncementREG - AstraZeneca PLC - Roxadustat pooled analyses: no increased CV risk
AnnouncementREG - AstraZeneca PLC - Roxadustat significantly increased haemoglobin
AnnouncementREG - AstraZeneca PLC - Calquence data to show improved progression-free
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca divests rights to Seroquel and
AnnouncementREG - AstraZeneca PLC - Imfinzi and Imfinzi plus tremelimumab delayed
AnnouncementREG - AstraZeneca PLC - AstraZeneca year-to-date and Q3 2019 results
AnnouncementREG - AstraZeneca PLC - Farxiga approved in the US to reduce the risk of
AnnouncementREG - AstraZeneca PLC - Trastuzumab deruxtecan granted FDA Priority Review
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Fasenra approved in the US for self-administration
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
Announcement